Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol-Myers Squibb	$59.83 -2.7%	$57.69	$39.35 ▼ $63.33	$121.40B	0.43	11.67 million shs	10.81 million shs
MRK Merck & Co., Inc.	$93.44 -1.4%	$93.75	$81.04 ▼ $134.63	$236.04B	0.35	10.09 million shs	11.89 million shs
PFE Pfizer	$25.73 -1.0%	$26.28	$24.48 ▼ $31.54	$145.79B	0.61	40.13 million shs	37.26 million shs
ZTS Zoetis	$161.74 -1.6%	$166.92	$144.80 ▼ $200.33	$72.43B	0.94	2.57 million shs	2.38 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol-Myers Squibb	-2.68%	-0.03%	+7.80%	+6.30%	+9.97%
MRK Merck & Co., Inc.	-1.28%	+0.24%	+8.01%	-7.73%	-23.82%
PFE Pfizer	-1.05%	-0.78%	-0.54%	+1.40%	-8.16%
ZTS Zoetis	-1.61%	-3.12%	-5.80%	-9.56%	-10.81%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol-Myers Squibb	4.3362 of 5 stars	2.2	3.0	4.2	4.0	3.5	3.3	0.0
MRK Merck & Co., Inc.	4.9993 of 5 stars	4.3	3.0	4.2	3.9	3.3	3.3	3.8
PFE Pfizer	4.891 of 5 stars	2.3	3.0	4.2	4.2	2.8	3.3	3.1
ZTS Zoetis	4.8108 of 5 stars	3.5	5.0	4.2	0.4	4.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-3.29% Downside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	25.33% Upside
PFE Pfizer	2.50	Moderate Buy	$31.92	24.09% Upside
ZTS Zoetis	3.08	Buy	$215.90	33.48% Upside

Current Analyst Ratings Breakdown

Latest ZTS, MRK, PFE, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
2/27/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $205.00
2/18/2025	MRK Merck & Co., Inc.	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$128.00 ➝ $105.00
2/14/2025	ZTS Zoetis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$242.00 ➝ $244.00
2/14/2025	ZTS Zoetis	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$243.00 ➝ $238.00
2/12/2025	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $115.00
2/10/2025	MRK Merck & Co., Inc.	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/10/2025	MRK Merck & Co., Inc.	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/10/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
2/10/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$210.00 ➝ $200.00
2/7/2025	BMY Bristol-Myers Squibb	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol-Myers Squibb	$48.30B	2.51	$6.31 per share	9.48	$8.08 per share	7.40
MRK Merck & Co., Inc.	$64.17B	3.68	$3.24 per share	28.82	$14.85 per share	6.29
PFE Pfizer	$63.63B	2.29	$4.03 per share	6.38	$15.81 per share	1.63
ZTS Zoetis	$9.26B	7.82	$7.27 per share	22.26	$10.65 per share	15.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.82	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	13.88	9.44	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.24	8.49	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.47	29.57	23.96	2.78	26.86%	53.82%	18.86%	5/1/2025 (Estimated)

Latest ZTS, MRK, PFE, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/13/2025	Q4 2024	ZTS Zoetis	$1.37	$1.40	+$0.03	$1.29	$2.30 billion	$2.32 billion
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol-Myers Squibb	$2.48	4.15%	+6.38%	N/A	17 Years
MRK Merck & Co., Inc.	$3.24	3.47%	+5.73%	48.14%	14 Years
PFE Pfizer	$1.72	6.69%	+2.50%	121.99%	16 Years
ZTS Zoetis	$2.00	1.24%	+18.66%	36.56%	14 Years

Latest ZTS, MRK, PFE, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/7/2025	ZTS Zoetis	quarterly	$0.50	1.2%	4/21/2025	4/21/2025	6/3/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol-Myers Squibb	2.90	1.25	1.15
MRK Merck & Co., Inc.	0.79	1.36	1.15
PFE Pfizer	0.63	1.00	0.73
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol-Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol-Myers Squibb	0.09%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol-Myers Squibb	34,100	2.03 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
PFE Pfizer	88,000	5.67 billion	5.66 billion	Optionable
ZTS Zoetis	14,100	447.79 million	447.08 million	Optionable

ZTS, MRK, PFE, and BMY Headlines

Recent News About These Companies

Roxanne Lagano Sells 326 Shares of Zoetis Inc. (NYSE:ZTS) Stock

March 12 at 4:27 PM | marketbeat.com

Insider Selling: Zoetis Inc. (NYSE:ZTS) Director Sells 1,210 Shares of Stock

March 12 at 4:27 PM | marketbeat.com

Is Zoetis Inc. (ZTS) the Best Pharma Stock to Buy According to Hedge Funds?

March 12 at 2:57 PM | insidermonkey.com

Sequoia Financial Advisors LLC Has $34.15 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

March 12 at 6:38 AM | marketbeat.com

Roxanne Lagano Sells 326 Shares of Zoetis Inc. (NYSE:ZTS) Stock

March 12 at 6:16 AM | insidertrades.com

Prosperity Financial Group Inc. Has $226,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 12 at 6:11 AM | marketbeat.com

Natural Investments LLC Purchases Shares of 3,221 Zoetis Inc. (NYSE:ZTS)

March 12 at 5:50 AM | marketbeat.com

Citizens Financial Group Inc. RI Has $3.47 Million Stake in Zoetis Inc. (NYSE:ZTS)

March 12 at 5:12 AM | marketbeat.com

Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)

March 11 at 1:09 PM | seekingalpha.com

King Luther Capital Management Corp Sells 261,559 Shares of Zoetis Inc. (NYSE:ZTS)

March 11 at 6:03 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Dearborn Partners LLC

March 11 at 5:44 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Davis R M Inc.

March 11 at 5:26 AM | marketbeat.com

Clare Market Investments LLC Makes New $670,000 Investment in Zoetis Inc. (NYSE:ZTS)

March 11 at 5:25 AM | marketbeat.com

Daiwa Securities Group Inc. Increases Holdings in Zoetis Inc. (NYSE:ZTS)

March 11 at 5:07 AM | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Has $35.37 Million Holdings in Zoetis Inc. (NYSE:ZTS)

March 11 at 4:56 AM | marketbeat.com

FY2026 Earnings Estimate for Zoetis Issued By Zacks Research

March 11 at 2:23 AM | americanbankingnews.com

7,916 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Argentarii LLC

March 10 at 7:28 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Jackson Hole Capital Partners LLC

March 10 at 7:21 AM | marketbeat.com

Vista Investment Partners II LLC Invests $1.88 Million in Zoetis Inc. (NYSE:ZTS)

March 10 at 7:13 AM | marketbeat.com

Johnson Investment Counsel Inc. Trims Position in Zoetis Inc. (NYSE:ZTS)

March 10 at 6:40 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stock Position Lowered by Sound View Wealth Advisors Group LLC

March 10 at 5:35 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS, MRK, PFE, and BMY Company Descriptions

Bristol-Myers Squibb NYSE:BMY

$59.82 -1.69 (-2.74%)

Closing price 03/12/2025 03:59 PM Eastern

Extended Trading

$59.83 +0.00 (+0.01%)

As of 03/12/2025 07:43 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$93.44 -1.29 (-1.36%)

Closing price 03/12/2025 03:58 PM Eastern

Extended Trading

$93.60 +0.16 (+0.17%)

As of 03/12/2025 07:42 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.72 -0.27 (-1.02%)

Closing price 03/12/2025 03:59 PM Eastern

Extended Trading

$25.76 +0.03 (+0.12%)

As of 03/12/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$161.74 -2.65 (-1.61%)

Closing price 03/12/2025 03:58 PM Eastern

Extended Trading

$160.84 -0.90 (-0.56%)

As of 03/12/2025 07:42 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time